Impaired peripheral endothelial microvascular responsiveness in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 11, Issue 1, 2007, Pages 25-32

  Khalil, Z ^a,b,c   LoGiudice, D ^d   Khodr, B ^a   Maruff, P ^e   Masters, C ^a,b,f,g  

^a Department of Biochemistry and Molecular Biology ^*  (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF SHARJAH   (United Arab Emirates)

^d Melbourne Extended Care   (Australia)

^e CogState Ltd ^*  (Australia)

^f FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^g Centre for Neuroscience   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD VESSEL REACTIVITY; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VASODILATATION;

EID: 33847716690     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2007-11106     Document Type: Article

References (45)

1. K. Barnham, C. Masters and A. Bush, Neurodegenerative diseases and oxidative stress, Nat Rev Drug Discov 3 (2004), 205-214.
2. K. Blennowm, CSF biomarkers for mild cognitive impairment, Journal of Internal Medicine 256 (2004), 224-234.
3. H. Chen, Z. Khalil and R. Helme, The effect of ET & PKC on the vasoactive mechanisms of A-beta at skin microvasculature, Natl Med J China 77 (1997), 367-370.
4. S. Christen-Zaech, R. Kraftsik, O. Pillevuit et al., Early olfactory involvement in Alzheimer's disease, Can J Neurol Sci 30 (2003), 20-25.
5. C. Clark, S. Xie, J. Chittams et al., Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60 (2003), 1696-1702.
6. A. Collie, P. Maruff, R. Shafiq-Antonacci et al., Memory decline in healthy older people: implications for identifying mild cognitive impairment, Neurology 56 (2001), 1533-1538.
7. A. Collie, P. Maruff and J. Currie, Behavioral characterization of mild cognitive impairment, J Clin Exp Neuropsychol 24 (2002), 720-733.
8. F. Crawford, Z. Suo, C. Fang and M. Mullan, Beta-amyloid peptides and enhancement of vasoconstriction by endothelin-1, Ann N Y Acad Sci 826 (1997), 461-462.
9. F. Crawford, Z. Suo, C. Fang and M. Mullan, Characteristics of the in vitro vasoactivity of beta-amyloid peptides, Experimental Neurology 150(1) (1998), 159-168.
10. J. De la Torre, Critically attained threshold of cerebral hypoperfusion: can it cause Alzheimer's disease? Annals of the New York Academy of Sciences 903 (2000), 424-436.
11. R. Diaz-Arrastia and F. Baskin, New Biochemical Markers in Alzheimer's disease, Archives of Neurology 58 (2001), 354-356.
12. N.C. Fox, E.K. Warrington, P.A. Freeborough, P. Hartikainen, A.M. Kennedy et al., Presymptomatic hippocampal atrophy in Alzheimer's disease: a longitudinal MRI study, Brain 119 (1996), 2001-2007.
13. M. Gentile, C. Vecchione, A. Maffei et al., Mechanisms of soluble Beta-Amyloid Impairment of endothelial function, The Journal of Biological Chemistry 279 (2004), 48135-48142.
14. P. Grammas, T. Botchlet, P. Moore and P. Weigel, Production of neurotoxic factors by brain endothelium in AD, Ann NY Acad Sci 826 (1997), 47-55.
15. H. Hampel, A. Mitchell, K. Blennow et al., Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity, J Neural Transm 111 (2004), 247-272.
16. C. Iadecola, F. Zhang and K. Niwa, SOD1 rescues cerebral endothelial dysfunction in mice overexpressing APP, Nature Neurosci 2 (1999), 157-161.
17. N. Ida, T. Hartmann, J. Pantel, J. Schroder, R. Zerfass et al., Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay, J Biol Chem 271 (1996), 22908-22914.
18. H. Kanetaka, H. Matsuda, T. Asada et al., Effects of partial volume correction on discrimination between very early Alzheimer's dementia and controls using brain perfusion SPECT, Nucl Med Mol Imaging 31 (2004), 975-980.
19. Z. Khalil, H. Chen and R. Helme, Mechanisms underlying the vascular activity of beta-amyloid protein at the level of skin microvasculature, Brain Res 736 (1996), 206-216.
20. Z. Khalil, H. Poliviou, C. Mayard, K. Beyreuther, C.L. Masters and Q.X. Li, Mechanisms of peripheral microvascular dysfunction in transgenic mice overexpressing the Alzheimer's disease amyloid beta protein, J. Alzheimer's Disease 4 (2002), 467-478.
21. Z. Khalil, K. Sanderson, P. Isberg et al., Beta A4 25-35 modulates substance P effect on rat skin microvasculature in aged rats, Brain Research 651 (1994), 227-235.
22. M. Laakso, K. Partanen, P. Riekkinen et al., Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study, Neurology 46 (1996), 678-681.
23. Q.-X. Li, C. Maynard, R. Cappai et al., Intracellular accumulation of amyloidgenic A-beta fragment of AD precursor protein in the hippocampus of aged transgenic mice, Neurochem 72 (1999), 2479-2487.
24. G. McKhann, D. Drachmann, M. Folstein et al., Clinical diagnosis of Alzheimer's Disease: a report of the NINCDSADRDA Work Group under the auspices of the Department of Health and Human Services task force on Alzheimer's Disease, Neurology 34 (1984), 939-944.
25. M. Minami, M. Kimura, N. Iwamoto and H. Arai, Endothelin-1-LI in cerebral cortex of Alzheimer-type dementia, Prog Neuro-Psychopharmacol & Biol Psychiat 19 (1995), 509-513.
26. F. Pasquier, Early Diagnosis of dementia: neuropsychology, J Neurol 246 (1999), 6-15.
27. F. Pasquier and A. Delacourte, Non Alzheimer Degenerative Dementias, Curr Opinion Neurol 11 (1998), 417-427.
28. R.C. Petersen, G.E. Smith et al., Mild cognitive impairment: clinical characterization and outcome, Arch Neurol 56 (1999), 303-308.
29. H. Poliviou and Z. Khalil, Beta-amyloid modulates the vascular activity of acetylcholine at the level of the microvasculature, Alzheimer's Reports 1 (1998), 233-239.
30. H. Poliviou and Z. Khalil, Beta-amyloid protein fragments modulate the vascular activity of SP at the level of the microvasculature, Alz Rep 1 (1998), 33-40.
31. H. Poliviou and Z. Khalil, The involvement of endothelial and non-endothelial mechanisms in the vasoconstrictor activity of A beta protein, Alz Reports 2 (1999), 1-8.
32. J.M. Price, X. Chi, G. Hellermann and E.T. Sutton, Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production, Neurological Research 23(5) (2001), 506-512.
33. T.W. Robbins, M. James, A.M. Owen, B.J. Sahakian, L. McInnes and P. Rabbitt, Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers, Dementia 5 (1994), 266-281.
34. R. Scahill, J. Schott, J. Stevens et al., Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI, Proc Natl Acad Sci USA 99 (2002), 4703-4707.
35. L. Scinto, K. Daffner, D. Dressler et al., A potential noninvasive neurobiological test for AD, Science 11 (1995), 1051.
36. C. Smith, L. Stanyer and J. Betteridge, Soluble B-amyloid (AB) 40 causes attenuation or potentiation of noradrenalineinduced vasoconstriction in rats depending upon the concentration employed, Neuroscience Letters 367 (2004), 129-132.
37. T. Sobow, M. Flirski and P. Liberski, Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease, Acta Neurobiol Exp 64 (2004), 53-70.
38. Z. Suo, J. Humphrey, A. Kundtz et al., Soluble Alzheimer's beta-amyloid constricts cerebral vasculature in vivo, Neuro Lett 257 (1998), 77-80.
39. T. Thomas, G. Thomas, C. McLendon, T. Sutton and M. Mullan, Beta-Amyloid-mediated vasoactivity and vascular endothelial damage, Nature 380(6570) (1996), 168-171.
40. T. Thomas, C. McLendon, E. Sutton and G. Thomas, Cerebrovascular endothelial dysfunction mediated by beta-amyloid, Neuroreport 8 (1997), 1387-1391.
41. T. Thomas, C. McLendon, E. Sutton and G. Thomas, Beta-Amyloid-induced cerebrovascular endothelial dysfunction, Ann N Y Acad Sci 826 (1997), 447-451.
42. T. Thomas, E. Sutton, A. Hellermann and J. Price, Beta-amyloid-induced coronary artery vasoactivity and endothelial damage, J Cardiovasc Pharmacol 30 (1997), 517-522.
43. K.A. Welsh, N. Butters, R.C. Mohs, D. Beekly, S. Edland et al., The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery, Neurology 44 (1994), 609-614.
44. H. Wolf, V. Jelic, H. Gertz et al., A critical discussion of the role of neuroimaging in mild cognitive impairment, Acta Neurol Scand Suppl 179 (2003), 52-76.
45. World Health Organisation, The ICD-10 Classification of Mental and Behavioural disorders, 1992, Geneva.